Biopharmaceutical Contract Manufacturing Market | Competitive Dynamics and Global Outlook 2027
The global biopharmaceutical contract manufacturing market is estimated to be valued at US$ 5,625.0 Mn by the end of 2017 and this is expected to increase to US$ 15,467.8 Mn by the end of 2027, registering a CAGR of 10.6% in terms of value over the forecast period.
View Full Report ToC, Figures and Tables -
Global Biopharmaceutical Contract Manufacturing Market: Regional Forecast
The global biopharmaceutical contract manufacturing market has been studied across the key regions of North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is the largest regional market, estimated to be valued at US$ 5,039.3 Mn by 2027 end, with a CAGR of 9.8%. APEJ is the second largest market for biopharmaceutical contract manufacturing, with a growth rate of 12.2% anticipated during the 10 year forecast period.
Global Biopharmaceutical Contract Manufacturing Market: Forecast by Platform
The report segments the global biopharmaceutical contract manufacturing market on the basis of Platform into Mammalian and Microbial. Mammalian is the largest segment by platform, which is estimated to represent US$ 3,857.2 Mn or 68.6% share of the total market in 2017 and is projected to reach US$ 12,534.5 Mn or 81.0% share by 2027 end, expanding at a CAGR of 12.5% over the forecast period.
Need more Information about R.eport Methodology ?
Global Biopharmaceutical Contract Manufacturing Market: Forecast by Product Type
In terms of product type, the global biopharmaceutical contract manufacturing market is segmented into Growth Factors, Interferons, Monoclonal Antibodies, Recombinant Hormones, Vaccines, Insulin, and Others. Monoclonal Antibodies is the largest segment by product type, with revenues estimated to cross US$ 8,100 Mn by the end of the forecast period and a CAGR of 11.3%.
Global Biopharmaceutical Contract Manufacturing Market: Forecast by Application
The global biopharmaceutical contract manufacturing market is segmented on the basis of application into Clinical and Commercial. The Commercial segment will dominate the global market, with revenues in excess of US$ 12,000 Mn expected to be recorded by the end of 2027 resulting in a CAGR of 11.0%.
Request to view Sample Report -
Global Biopharmaceutical Contract Manufacturing Market: Forecast by Therapeutic Area
On the basis of therapeutic area, the global biopharmaceutical contract manufacturing market is segmented into Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, and Others. Oncology is the largest segment by therapeutic area, expected to be valued at US$ 1,111.1 Mn by the end of 2017. Oncology is also the most lucrative segment. Autoimmune Diseases is the second largest segment by therapeutic area with a market attractiveness index of 1.3.
Global Biopharmaceutical Contract Manufacturing Market: Competitive Landscape
The report features some of the leading companies operating in the global biopharmaceutical contract manufacturing market. Companies profiled include Lonza Group AG, Baxter Biopharma Solutions, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH, Biomeva GmbH, Probiogen AG, Cytovance Biologics, Inc., KBI Biopharma, Inc., WuXi Biologics, Abzena Plc, Vetter Pharma International GmbH, Sandoz International GmbH, Catalent, Inc., AbbVie Contract Manufacturing (An AbbVie Company), Ajinomoto Althea, Inc.
Biopharmaceutical Contract Manufacturing Market Report is available @ US$ 5000
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biopharmaceutical Contract Manufacturing Market | Competitive Dynamics and Global Outlook 2027 here
News-ID: 788463 • Views: 79
More Releases from Future Market Insights
How Changing Dynamics of Cable Testing Market are Reflecting on Growth Strategie …
Global Cable Testing Market: Introduction The cost of the substitution of cables that are concealed is very high. Faults in the cable, bending, kinking, and crushing, are not always visible, which has created the requirement for cable testing. Thus, cable testing helps check the cable functionality, cable quality, and cable conformity. Several times, cable testing by visual inspection is an effective way of identifying the actual problem before it causes any
How Transformative Trends in Self-Organising Network Market are Molding Strategi …
Self-Organising Network: Introduction With accelerated advancements and increasing complexities in the radio network technologies, such as those utilised for the development of LTE and 5G networks, which are used for planning, management, configuration, healing and optimisation, are required to be automated to facilitate efficiency. At present, suppliers are offering self-organising networks that possess the ability to offer optimum performance. Self-organising networks are use cases that perform network governance, including network planning,
Mining Vehicle AC Kits Market: Exploring the Impact of Trends on Strategies of K …
Mining Vehicle AC Kits Market: Introduction Cabin space in mining equipment has become more sophisticated in the recent past. The installation of mining vehicle AC kits has evolved from an optional feature to a necessary feature. Mining equipment manufacturers have made advancements in technology related to efficiency, performance and cost of air conditioning systems in order to make them affordable and economical to enable low-budget and compact installations without compromising on
Key Factors to Fuel Growth of the Talent Acquisition & Staffing Technology and S …
With the growing importance of recruiting and retaining top talent effectively and efficiently, smart hiring processes are the need of the hour. It is about time organisations move beyond merely scrutinising resumes. Salaries and benefits are important factors, but adopting ways that would make candidates an important part of the hiring process will attract the best talent. Studies reveal that due to discrepancies in existing Applicant Tracking Systems (ATS), hiring
More Releases for Biopharma
Biopharma Outsourcing Market Future Analysis to 2023 |Sartorius, Emcure Pharmace …
According to the Biopharma Outsourcing Market report, the global market is expected to witness a relatively higher growth rate during the forecast period. This Biopharma Outsourcing Market Report cover strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and
BioPharma Buffers Market Analysis and Forecast to 2023 with Key Players Merck Mi …
A report added to the rich database of Qurate Business Intelligence, titled “World BioPharma Buffers Market Research Report 2023 (covering USA, Europe, China, Japan, India, South East Asia and etc.)”, provides a 360-degree overview of the Global market. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. The authentic processes followed to exhibit various aspects
Biopharma Outsourcing Market to Witness Huge Growth By 2023 | Emcure Pharmaceuti …
HTF MI released a new market study on Global Biopharma Outsourcing Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates
Global Hereceptin Biosimilar Market Reports 2017- Mylan N.V., AryoGen Biopharma, …
The Hereceptin Biosimilar Market 2017 examines the performance of the Hereceptin Biosimilar market, enclosing an in-depth judgment of the Hereceptin Biosimilar market state and the competitive landscape globally. This report analyzes the potential of Hereceptin Biosimilar market in the present as well as the future prospects from various angles in detail. The Global Hereceptin Biosimilar Market 2017 report includes Hereceptin Biosimilar industry volume, market Share, market Trends, Hereceptin Biosimilar Growth aspects,
BioPharma Buffer Market 2017- Merck Millipore, Reliable Biopharma, Thermo Scient …
Apex Research, recently published a detailed market research study focused on the "BioPharma Buffer Market" across the global, regional and country level. The report provides 360° analysis of "BioPharma Buffer Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global BioPharma Buffer industry, and estimates the future trend of BioPharma Buffer market on
Arbutus Biopharma-Cancer Drugs Clinical Pipeline Insight
“Arbutus Biopharma-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Arbutus. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in prclinical phase. There is 1 cancer drug by Arbutus Biopharma which is commercially available in the